Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

NCT03679598 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Alpha-1 Antitrypsin Deficiency (AATD)
Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations
Emphysema or COPD

Interventions

DRUG: Alvelestat (MPH966)
OTHER: Placebo

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]
[object Object]
[object Object]